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Abstract
Background: Acute compartment syndrome is an orthopedic emergency requiring urgent fasciotomy to prevent
irreversible damage. In hematological malignancies, acute compartment syndrome caused by severe soft tissue
bleeding is extremely rare. We present a patient with chronic-phase chronic myeloid leukemia who had acute
compartment syndrome caused by severe soft tissue bleeding in her right forearm.
Case presentation: A 72-year-old Japanese woman was referred to our hospital with swelling and pain of her right
forearm without a previous history of trauma. She was diagnosed with chronic-phase chronic myeloid leukemia.
Extreme thrombocytosis was present, although no evidence of acquired von Willebrand disorder was found.
Compartment syndrome caused by soft tissue bleeding was confirmed. An emergency fasciotomy for
decompression was conducted. However, sustained postoperative bleeding occurred and required massive red cell
concentrate transfusion. As her platelet count decreased by cytoreductive therapy, complete hemostasis was
achieved.
Conclusions: Patients with an extremely high platelet count might be at high risk for severe bleeding
complications even without acquired von Willebrand disease. For the control of severe bleeding complications in
patients with myeloproliferative disorder, the importance of thrombocyte reduction should be recognized.
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Background
Acute compartment syndrome (ACS) most often develops
after significant traumas, particularly those involving long
bone fractures. This syndrome may also occur following
non-traumatic causes, although such incidents are less
frequent. ACS caused by leukemic infiltration of the mus-
cles is uncommon but has sometimes been documented
in acute leukemia or non-Hodgkin lymphoma [1–4]. It is
rare for ACS to occur in the chronic phase of chronic
myeloid leukemia (CML). Here we present a case of ACS
that resulted from severe soft tissue bleeding in a patient
with CML in the chronic phase.
Case presentation
A 72-year-old Japanese woman was referred to our hos-
pital by her general practitioner with a 10-day history of
swelling and pain in her right forearm without a previ-
ous history of trauma. A physical examination revealed
that her right forearm was tense and swollen from the
area directly proximal to her wrist to immediately below
her elbow (Fig. 1a). She complained of increasing pain
with passive extension and slight numbness of her
fingers. Computed tomography revealed a low-density
area in the muscles of the anterior aspect of her right
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forearm (Fig. 1b). Laboratory investigation showed a
white cell count of 184.5 × 109/L, including 1 % blast
cells, 2 % eosinophils, 6.5 % basophils, 2.5 % promyelo-
cytes, 14 % myelocytes, 18 % metamyelocytes, 44 %
neutrophils, 7.5 % monocytes, and 4.5 % lymphocytes. In
addition, her hemoglobin level was 66 g/L, and her
platelet count was 3610 × 109/L. Routine coagulation
parameters revealed slightly prolonged prothrombin
time (15.9 seconds, international normalized ratio 1.28).
However, her activated partial thromboplastin time
(32.6 seconds) was within the normal range of 24.0 to
35.0 seconds, as was her bleeding time (90 seconds).
Plasma fibrinogen and D-dimer levels were slightly ele-
vated to 390.8 mg/dL and 3.3 μg/mL, respectively
(normal 200 to 380 mg/dL and 0 to 1.0 μg/mL, respect-
ively), although her fibrin degradation product level was
within normal range (8.2 μg/mL). The von Willebrand
factor (vWF) antigen level was normal (111 %), and the
vWF ristocetin cofactor activity, at 70 %, was undimin-
ished. Multimeric analysis of vWF did not show a de-
crease of large vWF multimers. Furthermore, factor 8
and 13 activities, at 82 % and 72 % respectively, were not
reduced. Laboratory values are summarized in Table 1.
She did not have any apparent skin and mucosal
bleeding tendency such as petechial hemorrhage. Bone
marrow aspiration revealed hypercellularity with marked
myeloid proliferation, but only 3 % of the cells were
blasts (Fig. 2). These findings led to the presumption of
a myeloproliferative disorder (MPD) such as CML,
polycythemia vera, or essential thrombocytosis (ET).
Because the level of her neutrophil alkaline phosphatase
score was markedly reduced to 49 (normal 150 to 350),
we deemed CML to be the most likely diagnosis.
Cytoreductive therapy with hydroxyurea (1500 mg/
day) was initiated as the most credible therapy to reduce
her platelet count, because we could not rule out the
possibility of MPD which does not respond to tyrosine
kinase inhibitors. An urgent orthopedic opinion was ob-
tained, and compartment syndrome was confirmed after
the compartment pressure was found to be 39 mmHg.
Emergency fasciotomy for decompression of the anterior
compartment was conducted, which confirmed a tense
Fig. 1 a Swollen right forearm of the patient. b Computed tomography revealing marked swelling of the right forearm compared with the
left forearm
Table 1 Laboratory values on admission
Values References
White cell count (109/L) 184.5 35–91
NAP score 49 150–350
Hemoglobin (g/L) 66 113–152
Hematocrit (%) 23.2 33.4–44.9
Platelet count (109/L) 3610 130–369
Bleeding time (seconds) 90 0–300
Prothrombin time (seconds) 15.9 10.5–13.5
INR 1.28 0.9–1.1
aPTT (seconds) 32.6 24–35
Fibrinogen (mg/dL) 390.8 200–380
FDP (μg/ml) 8.2 0–10
D-dimer (μg/ml) 3.3 0–1
Antithrombin III (%) 118.7 70–120
Factor VIII activity (%) 82 60–150
Factor XIII activity (%) 72 70–140
vWF: antigen (%) 111 50–150
vWF: Rco activity (%) 70 60–170
LDH (IU/L) 565 106–211
Albumin (g/dL) 4.0 4–5
Creatinine (mg/dL) 0.54 0.4–0.9
C-reactive protein (mg/dL) 0.23 0–0.3
aPTT activated partial thromboplastin time, FDP fibrin degradation product,
INR international normalized ratio, LDH lactate dehydrogenase, NAP neutrophil
alkaline phosphatase, Rco ristocetin cofactor, vWF von Willebrand factor
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compartment and pathologically proven hematoma in
the right anterior compartment. There was no evidence
of leukemic cell infiltration.
Persistent local bleeding developed during the latter
part of the operation despite no surgical cause. After de-
compression, the wound was left open and managed
with a wet dressing. Sustained postoperative oozing of
blood resulted in hypovolemic shock and required
massive red cell concentrate transfusion for hematologic
and cardiovascular resuscitation. She continued to re-
quire 4 to 8 units of red blood cell concentrate on a
daily basis (in Japan, 1 unit of red cell concentrate is
derived from 200 mL of donated whole blood).
Chromosome analysis of her bone marrow cells demon-
strated a karyotype of 46,XX,t(9;22)(q34;q11.2) (Fig. 3a).
In addition, fluorescence in situ hybridization detected a
BCR–ABL fusion signal in 93 % of the cells (Fig. 3b). Thus,
Fig. 2 Bone marrow aspirate (May-Giemsa staining) showing marked
myeloid proliferation without any differentiation block
Fig. 3 a G-banded karyotype showing 46,XX,t(9;22)(q34;q11.2). Red arrows indicate involved chromosomes 9 and 22. b Fluorescence in situ
hybridization using the Vysis Extra Signal probe showing the BCR–ABL fusion signal. Red arrow indicates a red–green fusion (yellow) signal which
confirms a BCR (green)/ABL (red) translocation
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she was diagnosed with chronic-phase CML [5]. Following
this definitive diagnosis, dasatinib therapy (100 mg/day)
was initiated. Although there were no signs of improve-
ment in the oozing of blood while her platelet count
remained high, her bleeding tendency began to improve
after her platelet count decreased to less than approxi-
mately 1000 × 109/L. During her clinical course her coagu-
lation parameters remained stable. Although her D-dimer
level, which reflects the dissolution of blood clots,
remained slightly elevated (0 to 3 μg/mL) for a period of
time, her prothrombin time and fibrinogen levels soon re-
covered to their normal range. Complete hemostasis was
achieved 7 days after the fasciotomy, and the fasciotomy
site was closed on postoperative day 20.
She continued dasatinib therapy, with good hematological
and molecular responses. She obtained complete cytogenetic
response and major molecular response at 12 and
18 months, respectively, after the initiation of dasatinib
administration.
Discussion
With patients with MPD, common complications
involve gastrointestinal bleeding or skin and mucosal
bleeding [6, 7]. Although most bleeding complications
are generally not severe in patients with MPD [8], some
do experience more severe symptoms [6].
In our patient, an extremely high platelet count
(>1000 × 109/L) and severe bleeding complications were
observed. According to the World Health Organization
Classification of Tumours: Pathology and Genetics of
Tumours of Haematopoietic and Lymphoid Tissues
(fourth edition), accelerated-phase CML is defined by
the presence of one or more of six specific features
including persistent thrombocytosis (>1000 × 109 cells/L)
that is unresponsive to therapy [5]. In our patient, her
platelet count was reduced in response to a tyrosine kin-
ase inhibitor, and this response was sustained. The diag-
nosis of chronic-phase CML was considered appropriate.
ACS is a limb-threatening and life-threatening emergency
resulting from elevated intracompartmental pressure. ACS
most often develops soon after significant traumas, but
might arise as a complication of an underlying disease, such
as soft tissue bleeding. In hematological malignancies, the
causes of ACS are divided into two types: tumor cell
infiltration or soft tissue bleeding. There are some case re-
ports of ACS caused by tumor cell infiltration [1–4]. How-
ever, to the best of our knowledge, there have been only
three case reports of ACS caused by soft tissue bleeding as-
sociated with hematological malignancies (Table 2). ACS
caused by malignant cell infiltration has been reported in
cases of acute leukemia or non-Hodgkin lymphoma [1–4].
In contrast, all three cases of ACS caused by soft tissue
bleeding were patients with MPD. One case involved a pa-
tient with ET with extreme thrombocytosis [9]. In another
case, thrombocytosis was not observed, but marked reduc-
tion of platelet aggregation function was present [10].
Elevated platelet count is regarded as a risk factor for
bleeding and thromboembolic events in MPD, but the
significance of a high platelet count has not been con-
firmed in clinical studies [6]. Michiels et al. reported that
hemorrhagic complications more often occur in patients
with higher degrees of thrombocytosis than in those with
lower degrees [11, 12]. Platelet dysfunction due to ac-
quired von Willebrand syndrome (AvWS) is considered
one of the reasons for bleeding tendency in patients with
MPD with remarkable thrombocytosis [13, 14], owing to
the increased number of platelets binding to highly
prothrombotic ultra-large vWF and their removal from
plasma [15]. However, neither decreased vWF levels
(antigen and activity) nor an absence of higher molecular
weight vWF multimers was confirmed in our patient.
These results suggest that factors other than AvWS were
responsible for the bleeding tendency of our patient.
Ristocetin-induced platelet aggregation abnormality is
characteristic of AvWS platelet aggregation studies in
vitro. In patients with MPD, various platelet function de-
fects including platelet hyperactivity and hypoactivity, in
addition to ristocetin-induced platelet aggregation, are
frequently observed [16–18]. MPD-associated platelet
dysfunction might cause bleeding complications. A
patient with CML with platelet function abnormalities
who developed severe soft tissue bleeding followed by
compartment syndrome has been reported [10]; this
patient did not experience AvWS-related complications.
Following the administration of a tyrosine kinase inhibitor,
platelet function improved together with the molecular
response of CML. Moreover, in four patients with MPD
with acute hemorrhagic or thrombotic complications of
Table 2 Acute compartment syndrome caused by soft tissue bleeding related with hematological malignancies







1 86/F Left forearm ET 3390 – Plateletpheresis [9]
2 32/M Left thigh CML (CP) 142 + Activated recombinant
factor VII
[10]
3 11/M Left calf CML (CP) ND + [20]
Present case 72/F Left forearm CML (CP) 3610 +
CML chronic myeloid leukemia, CP chronic phase, ET essential thrombocytosis, F female, M male, ND not described
Nagase et al. Journal of Medical Case Reports  (2016) 10:201 Page 4 of 6
thrombocytosis, clinical symptoms improved with correc-
tion of platelet function after plateletpheresis [19]. These
findings suggest that bleeding complications in patients
with MPD could be improved by reducing the platelet
count through correction of platelet dysfunction.
In the present case, prothrombin time was slightly pro-
longed, but activated partial thromboplastin time was
within the normal range. Bleeding time was also normal,
as measured using the Duke method. Our decision to per-
form the fasciotomy for decompression was based on
these findings. However, sustained postoperative oozing
occurred, and massive red cell transfusion was required.
The cause of slightly prolonged prothrombin time on
admission may be the decreased level of coagulation factor
VII, although we did not investigate this. During our pa-
tient’s clinical course her prothrombin time quickly recov-
ered to the normal range while oozing was still observed.
Therefore, coagulation factor VII was not relevant to her
bleeding tendency. In vitro platelet aggregation studies
could not be conducted in our patient, but it is possible
that her bleeding tendency might be caused by platelet
dysfunction with MPD-associated thrombocytosis for the
following three reasons: (i) although cessation of bleeding
was not achieved while her platelet count remained high,
hemostasis was achieved as her platelet count decreased;
(ii) the abnormality of the coagulation parameters was
imperceptible throughout her clinical course; and (iii) a
patient with CML with platelet dysfunction reported by
Ng et al. also showed a similar clinical course [10].
For the control of severe bleeding complications such as
ACS in patients with MPD with thrombocytosis, it should
be noted that bleeding tendency will probably last until
the platelet count is sufficiently reduced. Because of hypo-
volemic shock due to sustained bleeding we hesitated to
perform plateletpheresis. We should proactively consider
treatment options such as plateletpheresis in addition to
cytoreductive therapy before emergency fasciotomy.
Conclusions
Patients with an extremely high platelet count might be
at high risk for severe bleeding complications such as
compartment syndrome even without acquired von
Willebrand disease. For the control of severe bleeding
complications in patients with MPD, the importance of
thrombocyte reduction should be recognized.
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